Nipocalimab is a long-acting anti-FcRn pipeline ... IV), and successfully received approval in Japan. However, its subcutaneous trial (ADVANCE-SC trial studying the subcutaneous formulation ...

Johnson & Johnson's FcRn inhibitor nipocalimab has been awarded fast-track status by the FDA as a treatment for Sjögren's disease (SjD), an autoimmune condition that affects millions of people ...

The FDA has granted fast-track designation to nipocalimab for the treatment of Sjögren’s disease, according to a press release from Johnson & Johnson. The announcement comes 5 months after the ...

Johnson & Johnson JNJ announced that the FDA has granted a Fast Track designation (“FTD’) to its investigational drug, nipocalimab, for treating adult patients with moderate-to-severe Sjögren ...

FDA grants Fast Track designation to J&J’s nipocalimab for moderate-to-severe Sjögren’s disease, boosting its regulatory pathway. Phase 2 trial shows over 70% improvement in disease activity ...

SPRING HOUSE, Pa. - Johnson & Johnson (NYSE: NYSE:JNJ) has released new data on nipocalimab, an investigational drug with potential to treat diseases driven by immunoglobulin G (IgG) antibodies.

Johnson & Johnson (NYSE:JNJ) said on Tuesday that it received U.S. FDA's Fast Track designation for nipocalimab to treat adult patients with moderate-to-severe Sjögren's disease. In November last ...

SPRING HOUSE, Pa. - Johnson & Johnson (NYSE: JNJ) shared new data on nipocalimab’s efficacy in treating generalized myasthenia gravis (gMG), an autoimmune disorder. The findings were part of 12 ...

The FDA's granting of Fast Track Designation for nipocalimab to treat Sjogren's disease marks a significant advancement, following its earlier Breakthrough Therapy Designation. This recognition ...